Leukemia in children treated with growth hormone

Trends in Endocrinology and Metabolism

Volumn 9, Issue 9, 1998, Pages 367-370

  Blethen, Sandra L ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; GROWTH HORMONE RECEPTOR; RECOMBINANT GROWTH HORMONE;

ANIMAL CELL; ANIMAL TISSUE; BLOOM SYNDROME; DISEASE ASSOCIATION; DOSE RESPONSE; DOWN SYNDROME; FANCONI RENOTUBULAR SYNDROME; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE DEFICIENCY; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKEMIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; REPRODUCIBILITY; REVIEW; RISK ASSESSMENT; RISK FACTOR;

EID: 0032213845     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1043-2760(98)00091-5     Document Type: Review

References (27)

1. Allen DB, Rundle AC, Graves DA, Blethen SL Risk of leukemia in children treated with growth hormone: review and reanalysis. J Pediatr. 131:1997;S32-S36.
2. August GP, Lippe BM, Blethen SLet al. Growth hormone treatment in the United States: demographic and diagnostic features of 2331 children. J Pediatr. 116:1990;899-903.
3. Bechensteen AG, Halvorsen S., Abdelnoor M., Skottner A. Growth hormone treatment and the development of malignancy: recombinant human growth hormone does not induce leukemia in AK2/O-mice. Pediatr Hematol Oncol. 10:1993;41-47.
4. Bhatia S., Robison LL, Oberlin O.et al. Breast cancer and other second neoplasms after childhood Hodgkin's disease. New Engl J Med. 334:1996;745-751.
5. Blatt J., Olshan A., Gula MJ, Dickman PS, Zaranek B. Second malignancies in very long-term survivors of childhood cancer. Am J Med. 93:1992;57-60.
6. Blethen SL, Compton P., Lippe BM, Rosenfeld RG, August GP, Johanson A. Factors predicting the response to growth hormone (GH) therapy in prepubertal children with GH deficiency. J Clin Endocrinol Metab. 76:1993;574-579.
7. Blethen SL, Allen DB, Graves DAet al. Safety of recombinant deoxyribonucleic acid-derived growth hormone: the National Cooperative Growth Study experience. J Clin Endocrinol Metab. 81:1996;1704-1710.
8. Bozzola M., Tettone K., Severi F.et al. Does growth hormone treatment increase chromosomal abnormalities? Clin Endocrinol. 47:1997;363-366.
9. Breatnach F., Chessells JM, Greaves N. The aplastic presentation of childhood leukemia: a feature of common-ALL. Br J Haematol. 49:1981;387-393.
10. Butturini A., Bernasconi S., Izzi G., Gertner JM, Gale RP Short stature, Fanconi's anaemia, and risk of leukaemia after growth hormone therapy. Lancet. 343:1994;1576.
11. Estrov Z., Meir R., Barak Y., Zaizov R., Zadik Z. Human growth hormone and insulin-like growth factor-I enhance the proliferation of human leukemic blasts. J Clin Oncol. 9:1991;394-399.
12. Ford AM, Bennett CA, Price CM, Bruin MC, Van Wering ER, Greaves M. Fetal origins of the TEL-AML1 fusion gene in identical twins with leukemia. Proc Natl Acad Sci U S. A 95:1998;4584-4588.
13. Fradkin JE, Mills JL, Schonberger LBet al. Risk of leukemia after treatment with pituitary growth hormone. J Am Med Assoc. 270:1993;2829-2832.
14. Friedman GD: 1994. Making sense out of statistical associations. In Primer of Epidemiology. New York, McGraw-Hill, pp 213-217.
15. Frisch H. Pharmacovigilance: the use of KIGS (Pharmacia and Upjohn International Growth Database) to monitor the safety of growth hormone treatment in children. Endocrinol Metab. 4(Supp B):1997;83-86.
16. Giesbert S., Panzer S., Kovar H.et al. Acute leukemias express a functional receptor for the human growth hormone. Ann Hematol. 74:1997;253-257.
17. Greaves M. A natural history for pediatric acute leukemia. Blood. 82:1993;1043-1051.
18. Kubota M., Fujii K., Yamanaka C.et al. Leukemia in children with growth hormone deficiency not treated with growth hormone. Eur J Pediatr. 154:1995;418-422.
19. Mancilla EE, Orlando S., Albright AL, Menon RK, Sperling MA Leukemia and craniopharyngioma: coexistence in the absence of human growth hormone therapy or irradiation [abst]. Pediatr Res. 35:1994;103A.
20. Mercola KE, Cline MJ, Golde DW Growth hormone stimulation of normal and leukemic human T-lymphocyte proliferation in vitro. Blood. 58:1981;337-340.
21. Rapaport R., Oberfield S., Robison L.et al. Relationship of growth hormone deficiency and leukemia. J Pediatr. 126:1995;759-761.
22. Ron E., Modan B., Boice JD Mortality after radiotherapy for ringworm of the scalp. Am J Epidemiol. 127:1988;713-725.
23. Tedeschi B., Spadoni GL, Sanne MLet al. Increased chromosome fragility in lymphocytes of short normal children treated with recombinant human growth hormone. Hum Genet. 91:1993;459-463.
24. Watanabe S., Tsunematsu Y., Komiyama A., Fujimoto J. Leukaemia occurrence among growth hormone users. Lancet. 1:1988;1159.
25. Watanabe S., Mizuno S., Oshima L.-H., Tsunematsu Y., Fujimoto J., Komiyama A. Leukemia and other malignancies among GH users. J Pediatr Endocrinol. 6:1993;99-108.
26. Wilton P: 1994. Panorama of the diagnoses in the Kabi International Growth Study. In Progress in Growth Hormone Therapy-5 years of KIGS (Ranke MB and Gunnarsson R, eds). Mannheim, Germany: J & J Verlag, p 291.
27. Wolden SL, Lamborn KR, Cleary SF, Tate DJ, Donaldson SS Second cancers following pediatric Hodgkin's disease. J Clin Oncol. 16:1998;536-544.